Thursday, 30 June 2022

New Study: Aerosolized Cannabis Significantly Reduces Pain Levels

TESTSTSARDSAR

New Study: Aerosolized Cannabis Significantly Reduces Pain Levels by Frank Schuler

Cannabis inhalers are not necessarily a new technology. However, they are definitely newer than some other consumption methods. It’s an emerging technology in the cannabis space.

Many medical cannabis patients would likely prefer to use an inhaler versus smoking cannabis, and I am sure that many medical professionals would prefer that patients use inhalers as well.

Researchers in Israel recently conducted a study involving a specific type of cannabis inhaler to measure its efficacy on pain among neuropathy patients. Below is more information about it via a news release from NORML:

Haifa, Israel: The administration of aerosolized cannabis via a novel inhaler is associated with long-term pain reductions in patients with neuropathy and other chronic conditions, according to data published in the journal Pain Reports.

Israeli investigators assessed the efficacy of cannabis delivered via a novel metered selective dose inhaler (The Syqe Inhaler) in a cohort of chronic pain patients. The mean daily stable dose used by patients in the study was 1.5 mg of aerosolized delta-9-THC.

Use of the inhaler over a period of several months was associated with reduced pain scores and improvements in patients’ quality of life.

Some patients reported mild side-effects (typically dizziness and sleepiness) at the onset of the study, but few participants continued to report these effects throughout the duration of the trial.

Authors concluded: “Medical cannabis treatment with the Syqe Inhaler demonstrated overall long-term pain reduction[s], quality of life improvement[s], and opioid-sparing effect[s] in a cohort of patients with chronic pain, using just a fraction of the amount of MC [medical cannabis] compared with other modes of delivery by inhalation.

These outcomes were accompanied by a lower rate of AEs [adverse events] and almost no AE reports during a long-term steady-state follow-up. Additional follow-up in a larger population is warranted to corroborate our findings.”

According to recently compiled survey data, nearly one in three chronic pain patients report using cannabis for treatment management. Among patients in U.S. states where medical cannabis access is permitted, over 60 percent are qualified to use it to treat pain.

Full text of the study, “Long-term effectiveness and safety of medical cannabis administered through the metered-dose Syqe Inhaler,” appears in Pain Reports. Additional information on cannabis and chronic pain is available from NORML.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/new-study-aerosolized-cannabis-significantly-reduces-pain-levels/


source https://renzverspaget.weebly.com/blog/new-study-aerosolized-cannabis-significantly-reduces-pain-levels

Wednesday, 29 June 2022

Women in Cannabis Expo Comes To Denvers Vibrant Cannabis Scene

TESTSTSARDSAR

Women in Cannabis Expo Comes To Denver’s Vibrant Cannabis Scene by Ebby Stone

Only 22% of leadership positions in the cannabis space are held by women, according to a 2021 MJBizDaily report. To encourage more diversity in the cannabis industry, the Women in Cannabis Expo (WICE) is bringing together women in leadership roles from around the country to share their insights. 

Founded by owner Brooke M. Westlake, WICE is one of the industry’s leading female-centric conferences. Westlake began her career in healthcare and has since launched a cannabis testing lab.

It was during this transition to the cannabis industry that Westlake realized a need for a national networking event where women could gather and find opportunities for career advancement. She is hosting four WICE events across the country this year.

When and Where

The Denver, Colorado WICE takes place June 30 at the Curtis Hotel. The Curtis is a beautiful and eclectic hotel located in the heart of downtown Denver. It features unusual designs and vibrant themed rooms just two blocks from Denver’s 16th street mall. 

The hotel venue is directly across the street from the Denver Performing Arts Complex, so attendees to WICE can pop over to catch an award-winning performance after the event.

Cultivators, retailers, scientists, and business owners are meeting at The Curtis to exhibit products and enjoy a full day of education and networking. 

Speakers

The Denver WICE conference is hosting a diverse group of inspiring speakers. Marketing Director with Cannabis Technology Partners Melody Erfani will be speaking about protecting your cannabis business. Founder and owner of DREGLO Cannabis Testing Lab Jillian Xavier is presenting on accounting fundamentals.  

Claire Hanson Esq., senior counsel for Clark Hill will discuss securities fraud in the cannabis space. Cannabis & Tech Today’s Editor-in-Chief Charles Warner will offer insider media and marketing advice.

Sephida Artis-Mills, president and co-founder of the National Cannabis Party will discuss how to balance motherhood with a fulfilling career in the industry. Those are just a few of the many speakers presenting at the WICE this Thursday. Find the full speaker line up on the WICE website.

Tickets Now on Sale

Tickets for the June 30 event are now available for $115 through eventbrite. The expo starts at 9 AM and concludes at 8 PM mountain time. Join the industry’s leading women entrepreneurs to connect, inspire, and learn together.

There are two more WICE events this year across the country. Review the WICE website to find an event near you.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/women-in-cannabis-expo-comes-to-denvers-vibrant-cannabis-scene/


source https://renzverspaget.weebly.com/blog/women-in-cannabis-expo-comes-to-denvers-vibrant-cannabis-scene

Germanys Burkhard Blienert Keynotes ICBC in Berlin

TESTSTSARDSAR

Germany’s Burkhard Blienert Keynotes ICBC in Berlin by Johnny Green

Germany is in the midst of the most robust and complex cannabis policy and industry endeavor in the history of humankind.

Policymakers and industry regulators in Germany have worked diligently since the 2021 election to craft the laws, rules, and regulations that will eventually govern a national adult-use cannabis industry.

Given the size of Germany’s economy and its geographical position in the heart of the European continent, Germany’s adult-use industry will instantly become the largest on the planet once it is launched.

Currently, only Canada has a nationwide adult-use cannabis industry that is open to anyone of legal age and involves products that are not just of the low-THC variety.

Legalization can never come soon enough, however, the pace at which Germany’s new coalition government has moved on the adult-use cannabis front is considerable given that the results of the 2021 election are not even one year old.

Lawmakers and regulators in Germany want to legalize cannabis in as sensible, effective, and efficient of a manner as possible, and that is not an easy thing to do in a nation that is home to over 83 million people and shares 9 borders with other countries.

Commissioner Burkhard Blienert

Fortunately for Germany, they have a very qualified and brilliant Commissioner on Narcotic Drugs at the Federal Ministry of Health helping oversee the legalization process, Burkhard Blienert.

We are extremely proud and honored to announce that Blienert will be the keynote speaker at the upcoming International Cannabis Business Conference in Berlin July 19-20, 2022.

Commissioner Blienert’s resume is extensive, as he has dealt intensively with questions of drug and addiction policy for roughly ten years.

In the 18th electoral term (2013-2017) he was a member of the German Bundestag and represented his parliamentary group as a full member of the Health Committee, the Culture and Media Committee and the Budget Committee.

Blienert was his group’s rapporteur on drug and addiction issues during this period.

Since 1990, Mr. Blienert has been a member of the Social Democratic Party of Germany (SPD).

He has worked for the SPD party executive committee and served as policy officer of the SPD group in the Land parliament of North Rhine-Westphalia, responsible for school and education, sports and petitions.

Blienert studied politics, modern history and sociology (Master’s) and completed the first state examination for lower secondary education in social sciences, history and pedagogy.

As a member of the German Bundestag, Blienert sat on the Board of Trustees of the Federal Agency for Civic Education (BpB), on the Administrative Council of the German National Library and the Hörfunkrat Deutschlandradio broadcasting council as well as on the Administrative Council of the German Federal Film Board (FFA).

Currently, he is a member of the Supervisory Board of the Federal Cultural Federation, the National Society of Labour Welfare (AWO), the United Services Union (ver.di), the association “Against Oblivion – For Democracy” of the German Thomas Mann Society as well as the Paderborn district council.

History in the Making

Commissioner Blienert is not new to our conference. Last year he participated in a truly historic panel in which, for the first time ever, representatives from every major political party in Germany took part in a cannabis-only policy discussion.

The discussion was held mere weeks before the 2021 election, the results of which we now have the benefit of knowing.

We are very proud of the fact that much of what was discussed at our panel in 2021 has since become part of the mainstream cannabis policy conversation in Germany.

We look forward to continuing the cannabis conversation at this year’s B2B event in July where our schedule will once again feature a number of policymakers that are directly involved in the effort to legalize cannabis in Germany.

Attendees will literally be able to get the most up-to-date information regarding what is going on in Germany directly from people involved in the process, including Germany’s current Drug Czar.

In addition to the Berlin B2B event, the International Cannabis Business Conference (ICBC) will also offer a one-day Global Investment Forum (GIF) on July 18, 2022.

The ICBC Global Investment Forum in Berlin will feature hand-picked cannabis companies participating in a pitch session in front of top investors on the ICBC Main Stage.

It is a tremendous opportunity for cannabis companies in the emerging cannabis industry to showcase their products/services in front of seasoned industry investors. The pitch session is also open to service providers looking for reliable and high-end clients.

At the conclusion of the B2B event, attendees will then be able to enjoy one of the International Cannabis Business Conference’s famous after-parties. This year’s B2B event after-party in Berlin will feature the multi-Grammy award-winning reggae band Morgan Heritage.

Over 5,000 attendees and 350 companies sponsors and exhibitors are expected at the Berlin International Cannabis Business B2B Conference alone.

International Cannabis Business Conference events are attended by leading policymakers, executives, and entrepreneurs from all over the world, with over 85 countries being represented at previous events.

The event series is the best way for innovators and inventors to get their products or services in front of the top influencers and decision-makers in the cannabis space, as well as for investors to network with aspiring entrepreneurs.

A cannabis industry revolution is sweeping Europe, and Germany is at the center of it. If you’re serious about succeeding in the cannabis industry, check out the International Cannabis Business Conference’s flagship program in Berlin in July.

Leading cannabis entrepreneurs and policymakers from around the world will be in attendance and the networking and educational opportunities will be unparalleled. Secure tickets now before they are sold out!

This article first appeared on Internationalcbc.com and is syndicated here with special permission.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/burkhard-blienert-keynotes-icbc-in-berlin/


source https://renzverspaget.weebly.com/blog/germanys-burkhard-blienert-keynotes-icbc-in-berlin

Tuesday, 28 June 2022

Cannabis Tourism: How a New Travel Trend Is Taking Off

TESTSTSARDSAR

Cannabis Tourism: How a New Travel Trend Is Taking Off by Michael O'Regan

Michael O’Regan, Swansea University

Legal cannabis consumption rose in the US and Europe during the COVID pandemic, with some people turning to marijuana to help them cope with lockdowns and broken routines. Meanwhile, fewer people today view the drug as harmful compared to previous decades.

These factors may have contributed to a trend towards cannabis-related tourism, with destinations developing new holiday products to tempt customers, and rising travel bookings to destinations where cannabis is legal. But there are risks for both destinations and tourists in embracing this trend.

Work by MMGY Travel Intelligence found 29% of leisure travellers are interested in cannabis-related tourism. A study by the Dutch government revealed that 58% of international tourists choose Amsterdam in order to consume drugs. And business in Dutch coffee shops has increased since the start of the pandemic.

Nine months after Illinois legalised recreational cannabis in January 2020, nearly 30% of purchases were by non-residents. Thailand has just announced it has legalised cannabis and is hoping this will boost tourism.

The tourism sector and specific destinations have reacted quickly to the demand for cannabis, hemp and CBD-related products by designing experiences that include those elements. They are also responding to the expected economic potential related to increased hotel occupancy, tax revenues, increased land values, business expansion, jobs and public health and safety benefits that could be connected to cannabis sales.

Yet although tourism to other destinations with legalised cannabis is growing in popularity, data is only beginning to be collected. And so far no destination is ready to be labelled as the “next Amsterdam”.

Big potential

While cannabis-related travellers are believed to be high spending and well educated, authorities don’t want to replicate the Dutch model, which led to massive concentration of cannabis coffee shops in Amsterdam and raised concerns over hard drug use and criminality.

New business models are focusing on agri-tourism (meet-the-farmer sessions) and culinary tourism and events such as cannabis festivals. Tourists can choose from farm tours, “bud and breakfast” hotels, city tours, cannabis festivals, cannabis trails, food, wine and marijuana pairings, “ganja yoga”, and packages that combine accommodation and cannabis experiences.

The potential for cannabis tourism is widespread around the world. More than 19 US states and Washington DC have now legalised recreational cannabis, along with Canada, Mexico, Uruguay and others. In Europe, Luxembourg allows the consumption of personally cultivated cannabis, while Switzerland is trialling cannabis sales from pharmacies for recreational purposes.

Malaysia and Thailand have made initial steps towards legalising recreational use. Costa Rica and Morocco have also approved legalisation for medicinal purposes.

Risks for tourists

However, few countries have clarified the legality of cannabis use by tourists with legislation directed at recreational use by residents. This means tourists risk breaking the law unintentionally, by interacting with street dealers and police as well as the health implications of consuming real and fake drugs.

There is some evidence cannabis can improve some mental health conditions and provide pain relief. But tourists with pre-existing mental health disorders, for example, may risk their physical and psychological wellbeing. Cannabis-related mental health events including depression can also occur among those who have not been diagnosed with mental health issues.

A patchwork of complicated laws and regulations regarding recreational cannabis use by overseas tourists means questions remain about the legality of consumption, the transport of cannabis vape pens overseas as well as issues of insurance cover and health care, during and after travel.

While Uruguay is planning to allow consumption by tourists, countries like Portugal, where cannabis has been decriminalised since 2001, still doesn’t allow them to buy it legally. In Spain, cannabis clubs allow visitors to donate to the club instead of purchasing a product. But Spain and other large markets like South Africa are focused on domestic cannabis tourism rather than international visitors.

Few countries have carried out a cost-benefit analysis around legal cannabis and tourism, or fully discussed issues of land and water use, police powers and benefits to local communities. While cannabis tourism can generate tourism and jobs, and reduce the power of organised crime, the goal of sustainable development is threatened by theft, racism, and a market stacked against small local operators who often can not secure funding or insurance. There are also possible increases in pollution and public health and safety concerns.

Mexico and Canada have promised funding for indigenously owned businesses to aid social and racial equality, while New York plans to create a US$200 million (£162 million) public-private fund to support social equity goals. Resident support, and continual conversations with communities on how to plan the sustainable development of cannabis tourism should be a vital part of development of the sector.

While it appears that the COVID pandemic helped stimulate and legitimise the use of marijuana, with dispensaries declared an essential service in parts of the US during the pandemic, tourism could expand and normalise acceptance of its use.

Perceived risks may fade and and tourist guilt may dissipate. Cannabis tourism is likely to become just another segment of the holiday industry.The Conversation

Michael O’Regan, Senior Lecturer in International Tourism Management, Swansea University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/cannabis-tourism-how-a-new-travel-trend-is-taking-off/


source https://renzverspaget.weebly.com/blog/cannabis-tourism-how-a-new-travel-trend-is-taking-off

World Record Bid Rejected Due To Outdated Cannabis Policy

TESTSTSARDSAR

World Record Bid Rejected Due To Outdated Cannabis Policy by Aron Vaughan

Shortly after its inception in 1955, Guinness World Records, formerly known as the Guinness Book of World Records, became the authority on achievements that land outside traditional sporting records and a veritable encyclopedia of all things wondrous and weird. 

When someone asks Google, “Who is the oldest person ever?” Or, “What is the largest living cat?,” the Guinness World Records inevitably has the answer. 

But, as time passes and new industries grow and thrive, Guinness is planting its feet squarely in the past.

Atomic Closer

STM Canna recently submitted an application for its Atomic Closer pre-roll machine to be entered into the record books for the ability to close the most pre-rolled cones in under a minute. The machine is capable of closing 72 pre-rolls in 45 seconds, a feat unrivaled by competitors.

The Atomic Closer also tamps and crown-folds ends into a consistent fold instead of twisting them. The result is an even burn from the first inhalation instead of wasted tokes.

Outdated Policy

Guinness World Records rejected the application based on its policy of disqualifying any records pertaining to the preparation or consumption of tobacco, cannabis, or CBD.

“Guinness World Records no longer accepts applications or creates new record titles that are related to the consumption, preparation or use of tobacco, cannabis or nicotine products,” according to the Guinness World Records policy page on its official website.

In rejecting STM’s bid, it is missing the opportunity to highlight the achievements of innovation and technology in the cannabis industry.

Furthermore, the organization lumps cannabis and tobacco — two very different plants — together. This perpetuates an outdated stigma about the unfounded dangers of cannabis and CBD use.

Responsible Policy

Many of the regulations set by the Guinness World Record Committee are in place for good reason. Policies that protect animals from abuse and safeguard the wellbeing of participants speak to the common sense and ethical responsibility of the organization, but policies against cannabis — and especially CBD — come across as archaic and misinformed.

Guinness World Record policies also deny applications involving alcohol consumption — an ironic policy considering the former owner of the company — and excessive eating. No one believes it would be reasonable to allow applicants to attempt drinking the most shots in recorded history, or eating the most hotdogs in 24 hours. It would also be irresponsible to let veteran stoners battle it out for the title of “Consumer of the Largest Amount of Cannabis in 30 Minutes.”

It’s the word “preparation” in the clause of the cannabis and tobacco policy that is stifling the creativity, ingenuity, and skill of people within the cannabis industry.

Going Backward

In addition to the rejected bid from Guinness World Records, STM Canna has been hit by YouTube with several policy violations, citing dangerous or harmful content on the channel.

“Content intending to sell illegal or regulated goods and services, such as drugs or pharmaceuticals without a prescription, is not allowed on YouTube,” according to the platform’s terms of service. However, STM’s products are not illegal, and its YouTube channel is used primarily to provide demonstrations of its machinery. The only link to STM in the descriptions of its videos takes viewers to its website, not a checkout page.

YouTube’s policy is in line with other social media platforms, raising a larger question of whether those polices are antiquated. Instagram recently banned Cannabis & Tech Today’s official page on June 25, giving little to no detail on the decision.

Let Cannabis Innovation Thrive

Last year, annual cannabis sales reached $26.5 billion, and are expected to reach $32 billion in 2022, according to Frontier Data. The industry is filled with innovators from a number of fields including, among many others, engineering, biochemistry, and computer science. Allowing record titles for cannabis can spur the brightest minds in the industry to continue innovating and surpassing their own achievements.

After the passage of the Farm Bill in 2018, hemp and CBD are federally legal, and as of June, cannabis is regulated for medical or adult use in 38 states. It is time to cast off the stigma and regulations of decades ago and let cannabis and the technology around it be recognized.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/world-record-bid-rejected-due-to-outdated-cannabis-policy/


source https://renzverspaget.weebly.com/blog/world-record-bid-rejected-due-to-outdated-cannabis-policy

Monday, 27 June 2022

PTSD and War Drive Ukraine To Medical Cannabis

TESTSTSARDSAR

PTSD and War Drive Ukraine To Medical Cannabis by Frank Schuler

Days ago Ukraine’s cabinet approved a draft medical cannabis bill, sending it to Parliament for consideration. Compared to other countries in the region, Ukraine has been very slow to reform its medical cannabis policies.

“The Cabinet of Ministers of Ukraine supported the bill that will regulate the circulation of cannabis plants for medical, industrial purposes, scientific and scientific-technical activities

This bill will expand patients’ access to the necessary treatment for a number of diseases, including cancer and post-traumatic stress disorder,” Ukraine’s Ministry of Health stated in a news release.

“We understand the negative consequences of war on the state of mental health. We understand the number of people who will need medical treatment as a result of this impact.

“And we understand that there is no time to wait. Therefore, we have already prepared a legislative basis to ensure a full cycle of cannabis-based drug production in Ukraine: from cultivation and processing to full-fledged production,” Minister of Healthcare Viktor Liashko wrote in a Facebook post about the measure.

“At the same time, we still propose to establish strict control over the cultivation, production and implementation of drugs, understanding the sensitivity of this issue in society and are ready to gradually develop this industry, showing the results of treatment and help oh to Ukrainian patients.

Not to import, but to do ours, Ukrainian! Historically, cannabis-based drugs have been used to reduce pain, spasms and muscle strains, treat anorexia, PTSD, and anxiety disorders. In addition, they are used in the treatment of individual types of epilepsy, glaucoma, psoriasis, parkinsonism, multiple sclerosis.

An important purpose of this medication is to alleviate the pain and suffering of seriously ill and palliative patients, including cancer patients and HIV patients.”

Viktor Liashko wrote on Facebook.

According to the Ukraine Ministry of Health’s news release, the measure would “License economic activities for the cultivation of varieties of plants of the genus Cannabis for medical purposes” as well as “authorize the cultivation of varieties of plants of the genus Cannabis for medical, industrial purposes, in scientific and scientific-technical activities.”

The measure now moves to Ukraine’s Parliament for consideration.

This article first appeared on Internationalcbc.com and is syndicated here with special permission.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/ptsd-and-war-drive-ukraine-to-medical-cannabis/


source https://renzverspaget.weebly.com/blog/ptsd-and-war-drive-ukraine-to-medical-cannabis

New Study: CBD Does Not Effect Driving Skills

TESTSTSARDSAR

New Study: CBD Does Not Effect Driving Skills by Frank Schuler

Responsible cannabis consumers recognize that operating a motor vehicle on a public roadway while being intoxicated by any substance, cannabis included, is not safe.

With that being said, just because someone has cannabis in their system does not automatically mean that they are too impaired to safely operate a motor vehicle.

That is demonstrated in the results of a recent study conducted in Australia. Below is more information about it via a news release from NORML:

Sydney, Australia: The oral administration of up to 1500 mg of CBD does not induce feelings of intoxication and is not associated with changes in simulated driving performance, according to data published in the Journal of Psychopharmacology.

A team of Australian researchers assessed the impact of varying dosages of CBD (ranging from 15 mg to 1500) versus placebo in 17 subjects. Study participants engaged in a series of simulated driving tests at approximately one hour and four hours after dosing. Investigators separately assessed subjects’ cognitive performance via their completion of a variety of computerized tasks. Participants were also asked whether they felt either “stoned” or “sedated” at any time during the trial.

Consistent with prior research, authors reported that CBD administration was not associated with either weaving or any other significant changes in simulated driving performance. Participants also failed to show any significant differences in either cognitive function or in their subjective feelings of well-being following CBD dosing.

Authors concluded: “The results of this study suggest that acute, oral CBD treatment at doses up to 1500 mg does not induce feelings of intoxication and is unlikely to impair cognitive function or driving performance. However, further research is required to confirm no effect of CBD on safety-sensitive tasks in the hours immediately post-treatment and with chronic administration.”

Full text of the study, “Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomized controlled trial,” appears in the Journal of Psychopharmacology. Additional information is available from NORML’s fact sheet, ‘Marijuana and Psychomotor Performance.’

This article first appeared on Internationalcbc.com and is syndicated here with special permission.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/new-study-cbd-does-not-effect-driving-skills/


source https://renzverspaget.weebly.com/blog/new-study-cbd-does-not-effect-driving-skills

Friday, 24 June 2022

Level Select CBD Review: Is THC-Free Worth It?

For all of the CBD industry’s advancements, few brands have actually answered the question, “How much of this should I take?”

Level Select CBD has set out to provide a simple answer, drastically simplifying the dosage confusion issue. 

Regardless of the reason you’re turning to CBD, the ability to try out one of three distinct potency levels and move up or down to find the perfect fit is among the most frequently repeated praises of Level Select’s CBD products by their customer base. 

Our assessment of the brand’s manufacturing practices, testing protocols, certifications and more reflected this attention to clarity and quality, but a few blatant issues across customer service, transparency, and other major criteria dropped the brand’s overall score to a 81.5.

To learn more about how they arrived at this core, here is our comprehensive review of Level Select CBD, complete with comments from our interviews with Kadenwood VP Jason Waggoner and Director of Ecommerce Bill Porter

Level Select CBD Review: Table of Contents

  1. Pros and Cons
  2. The Level Select CBD Story
  3. Level Select CBD Product Overview
  4. Our Level Select CBD Review

Level 2 CBD Oil Drop Tincture

Available in a 1200mg concentration, the Level 2 CBD Oil Drops from level select deliver a simple, but pointed formulation that lets the hemp do the work.

Our review team enjoyed the natural mint flavor, and the tincture was moderately effective in addressing everyday discomfort and stress.

Use code INSIDER3 to get a FREE product when you buy 2!

Pros/Cons

Let’s start with the pros:

  • Clear and consistent cannabinoid potency levels
  • Targeted, functional formulations (recovery, sleep, etc.)
  • Above-average certifications, testing protocols, and supply chain control
  • Prestigious medical advisory team and highly involved athlete ambassadors

And now the cons:

  • Smaller product catalog
  • Few botanical enhancers in tincture line (gummies have turmeric, ginseng, etc.).
  • Slow, unengaged customer service
  • Thin website content

The Level Select CBD Story

On the history of the brand, Waggoner explained to us that he and his team noticed early on in the CBD boom that supply chains and the products they rolled out were marred by bad actors and mass uncertainty.

“We are product innovators working in an industry where 30 million people have already used CBD,” he said, so much of their foundation was built on steering their slice of the industry away from the inconsistent products and, in the worst case scenario, plain-old snake oil. 

This is where the long-term focus on pure, high-quality, THC-free hemp extracts was born.

To address the issue of dosage confusion without making healthcare claims and/or presuming too much about the user’s motivations, Level Select came up with a simple way of indicating potency by assigning levels to products.

Most of their products are rated on a three-level scale so that any CBD user can clearly establish the potency they need to experience relief instead of browsing fifty different products that all feature different milligram-per-serving amounts. 

According to Waggoner, this approach was created in service to Level Select’s mission from day one, which is to spearhead the plant-based wellness movement. 

How Level Select Stands Out

While the majority of their competitors home in on increasingly targeted CBD product formulations to address conditions they aren’t allowed to explicitly mention (there’s a fun tightrope), Level Select prefers a more all-encompassing approach because they know the spectrum of CBD users is broadening all the time.

This is where the levels come in; regardless of the underlying issue, customers can simply find the potency that works for them and let the hemp extract do the rest. 

Another major differentiator that admittedly earned an eyebrow raise from our editorial team was the fact that Level Select’s athlete ambassadors actually participate in the meetings as part owners of the company.

Where most competing brands will have the picture of the athlete (using the product, of course), possibly a quote, and rarely anything more, Level Select’s ambassadors actually attend board meetings and offer substantive input as real users of the products and members of the company. 

It also doesn’t hurt that the Level Select Medical Advisory Team is led by the 17th Surgeon General of the United States, Dr. Richard Carmona. 

Finally, Level Select CBD is fully vertically integrated, which is a rare sight indeed. 

They not only own the growing operation, but as part of the Kadenwood family, they possibly have the largest CBD manufacturer in the country, selling isolate to many other CBD brands. 

It’s this structure that has helped them to achieve a strong certification profile that many competitors can’t get, including cGMP, BRCGS, NASC, and ISO-9001. 

Level Select CBD Product Overview

Level Select offers CBD sports roll-ons, sports creams, oil drops, gummies, pet products, and even CBD tea.

Customers can also shop on the website by “solution,” e.g., recovery, sleep, energy, and wellness. 

The level system applies to the roll-ons, creams, and oil drops.

Here’s a brief overview of some of their most popular products/categories.

Level Select Drops

Level 3 (Mint): 60mL/5000mg, Ingredients: MCT Oil, CBD Broad Spectrum Hemp Extract, Natural (Mint) Flavor

Level 2 (Mint): 30mL/1200mg, Ingredients: MCT Oil, CBD Broad Spectrum Hemp Extract, Natural (Mint) Flavor

Level 1 (Mint): 30mL/600mg, Ingredients: MCT Oil, CBD Broad Spectrum Hemp Extract, Natural (Mint) Flavor

Level Zzz: 30mL/900mg, Ingredients: MCT Oil, CBD Broad Spectrum Hemp Extract, Melatonin, Natural (Vanilla) Flavor

Level 3 CBD Oil Tincture

Their most potent CBD tincture, Level 3 CBD Oil Drops from Level Select offer a competitively priced option, coming in at less than three cents a milligram.

Our team felt the difference between this tincture and the Level 2.

Use code INSIDER3 to get a FREE product when you buy 2!

Level Select Sports Cream

Level 3: 3oz/1200mg, check here for ingredients.
Level 2: 3oz/600mg, check here for ingredients.
Level 1: 3oz/300mg, check here for ingredients.

Level 3 Sports Cream

Their most popular product, the Level 3 Sports Cream from Level Select CBD is relied upon for its potent effects against discomfort.

This formulation is ideal for active people as well as anyone dealing with ongoing discomfort.

Use code INSIDER3 to get a FREE product when you buy 2!

Level Select Sports Roll-Ons

Level 3: 2.5oz/1800mg, check ingredients here
Level 2: 2.5 oz/1200mg, check ingredients here
Level 1: 2.5oz/900mg, check ingredients here

Level 2 CBD Roll-On

The Level Select CBD Roll On brings menthol and CBD together for fast-acting discomfort relief in a convenient format.

The product rolls on smoothly, and rather than simply masking the discomfort for twenty minutes with strong tingling, provided longer-lasting relief.

Use code INSIDER3 to get a FREE product when you buy 2!

Level Select Gummies (60ct, 12.5mg/gummy)

Level ZZZ Restful Sleep, check ingredients here
Focused Energy, check ingredients here
Immune Support, check ingredients here

Level ZZZ Restful Sleep Gummies

All of Level Select’s CBD gummies are enhanced with functional ingredients, but we found the Level ZZZ Restful Sleep Gummies to be particularly effective.

For some, the higher 25mg/piece concentration might mean one piece in the evening is enough, but more experienced users can take two or three for more potent results.

Use code INSIDER3 to get a FREE product when you buy 2!

Our Level Select CBD Review

Throughout our week-long review period, we used the Level 2 Cooling Mint Sports Cream, the Level 2 Sports Roll-On, and the Restful Sleep Gummies with melatonin and lemon balm.

The gummies noticeably improved our time-to-sleep metric when we took 75mg or more in the late afternoon/early evening (each gummy provides 25mg); there was much less tossing and turning before falling asleep each night.

Taking into account our experience with CBD, we anticipate most users should be able to hit this threshold at 50mg, or two gummies.

The cooling mint sports cream was especially effective at relieving various forms of discomfort affecting soft tissue, including old sports injuries and those “just because you’re not young anymore and for no other reason” aches and pains. 

The roll-on was a bit sticky, but otherwise, both topicals provided 3-4 hours of discomfort relief that made it easier to work and/or go about daily chores without shifting around or as much or taking breaks.

Both in terms of taste/smell/texture and noticeable results provided, our experience with Level Select products is consistent with what we expect from upper-echelon CBD brands.

Now that you’ve heard about our personal experience, here’s our more in-depth dive into the brand behind the products, including a critical evaluation of their manufacturing and sourcing standards, pricing structure, customer service, and more.

Quality

Max Score = 35 points
Level Select = 32.5 points

Considering the ownership of the growing operation, CO2 and food-grade ethanol extraction methods, product certifications, and clean ingredient lists , there’s very little question that Level Select CBD products meet or exceed top quality standards.

However, they have very few options in terms of CBD products enhanced by supporting botanicals and other wellness-affirming compounds.

The gummy line is now introducing vitamin C, turmeric, melatonin, lemon balm, caffeine, and ginseng into the mix, which is a definitive step in that direction, but those looking for CBD oils with these enhancers won’t find them (except for melatonin). 

Finally, we applied a deduction for no USDA organic certification, but Kadenwood’s ownership of the growing operation mitigated the loss of points. 

Transparency

Max Score = 12.5 points
Level Select = 8.63 points

Though we were able to glean a lot of key insights into Level Select’s R&D process, sourcing, processing and more from our conversation with Kadenwood VP Jason Waggoner and Director of E-commerce Bill Porter, customers perusing the Level Select (and/or Kadenwood) site for this information may find it lacking.

Third-party lab reports are provided for some product batches, but not all, and product pages run on the slimmer side as far as descriptions and other supportive content goes.

Especially because Kadenwood’s vertical integration and the sheer size/scope of their operation is so impressive, we were miffed to see very little of this info (their huge facility, advanced hemp extraction/processing equipment, etc.,) detailed in depth on either site, other than a non-clickable image explaining they are vertically integrated. 

The same goes for the “about us” page, which—while it provides at least a decent introduction to the operation along with a feature of Dr. Richard Carmona (17th Surgeon General of the US) of their Medical Advisory Team—could have been far more illuminating and impressive considering what the brand has to brag about.

The redeeming factor here is that Level Select has all the credentials and resources they need to have a very impressive and engaging online presence, but until they actually communicate their value to the public and invest a bit more into consumer education and product support, their transparency will continue to suffer. 

Website Experience

Max Score = 7.5 points
Level Select = 6.75 points

We don’t harp too much on the finer points of web design, so as long as the rated brand’s website is non-distracting, our focus is on ecommerce functionality and educational/supportive content.

Browsing and purchasing products on the Level Select CBD is very easy and intuitive; we didn’t have to backtrack or click around at all to find the product information we needed, select said products, and check out.

The site is also well-adapted to mobile devices, although we did make a small deduction because the page featuring third-party lab reports had several formatting errors.

We typically like to see a dedicated “CBD 101” section of the site that’s directly reachable from the main navigation bar (the most obvious links usually at the top of the homepage), but because the blog features a “CBD 101” category and plenty of posts to date, we only applied a small deduction here as well.

Overall, our experience navigating the Level Select site was fluid and engaging.

Brand Value

Max Score = 25 points
Level Select = 18.25 points

Given their full ownership of the supply chain, their nano CBD technology (used in topicals), and their high-level involvement in the hemp legality conversation with minority leader Mitch McConnell and others, it’s hard to deny the major impact Level Select and Kadenwood are having on the CBD industry. 

Given their powerful positioning, however, it’s harder to justify their lack of participation in medical studies and philanthropic activities, which cumulatively resulted in a sizable deduction for brand value.

Even though they’re losing the trend-hopping crowd, for people who really need relief without the confusion or the added gimmicks, the simplicity and quality of Level Select CBD quietly draws in their audience. 

Having reviewed dozens of brands, our strongest impressions are that Level Select CBD truly believes in the power of the hemp plant, and that after the hyper-targeted formulations and buzz words fade away, real plant-based wellness will still be going strong. 

Pricing 

Max Score = 10 points
Level Select = 9.25 points

Here’s a sample of the pricing structure for the most popular product types available at Level Select:

Level 2 CBD Oil: $99.99/2400mg = $0.04/mg

Level 1 Oil: $69.99/1200mg = $0.06/mg

Level 3 Cream: $89.00/1200mg = $0.07/mg

Level 2 Cream: $59.99/600mg = $0.10/mg

Gummies: $49.99/1500mg = $0.03/mg

Especially in the case of the gummies, which are priced at an unprecedented level considering the quality and added enhancers, this entire range of products is competitively priced.

We expected prices to be a bit lower than average because of the simplicity of the formulations, but offsetting for quality, this is still a very solid value for anyone looking for a pure, THC-free hemp extract and no other “noise.”

Customer Service/Shipping and Return

Max Score = 10 points
Level Select = 6.125 points

Level Select ships to virtually any address in the world, and will estimate shipping/delivery dates based on availability of your items and shipping options you choose (no shipping window estimates provided).

Full refunds of new, unopened items are allowable within a 30-day window from the time or order (not receipt), and Level Select will pay return shipping costs if they are the cause of the issue.

We would like to see at least one live customer service option, however; the Level Select site currently offers a standard question/comment form that they respond to via email.

Our Level Select CBD Review Overall Rating

All tallied, Level Select CBD earned an overall rating of 81.5/100.

Here are some key takeaways to sum up our review:

  • High-quality THC-free products, sourcing, testing, and certifications
  • Historic COAs are not available
  • Site leaves some information to be desired
  • Seamless ecommerce experience
  • Customer service could be improved
  • Pricing is ideal for the quality

The biggest takeaway is that Level Select homes in on simplifying the confusion of finding the right dose and does it well.

What’s One Thing You Want People to Know About Hemp-Derived CBD?

We use this question as a way of putting each brand’s story into the greater context of the industry as a whole and the “broad spectrum” of consumers turning to CBD.

Here’s what Jason Waggoner told us:

“We’ve seen firsthand the difference in quality of life that our hemp extracts provide; we use the product ourselves.”



via The CBD Insider https://thecbdinsider.com/review/level-select-cbd-review/#utm_source=rss&utm_medium=rss&utm_campaign=level-select-cbd-review


source https://renzverspaget.weebly.com/blog/level-select-cbd-review-is-thc-free-worth-it

MLB Greenlights CBD Sponsorships

According to comments made earlier this week by Major League Baseball Chief Revenue Officer Noah Garden, the MLB is poised to enter the small, but growing selection of professional sports leagues that accept CBD sponsorships.

The league seems most interested in jersey patch sponsorship deals with CBD brands at the moment, though televised advertisements (during MLB games) are also on the table.

In order to qualify for a sponsorship deal with the MLB, CBD companies must fulfill two requirements at a minimum:

  • NSF (National Sanitation Foundation) certification
  • THC content must be under psychoactive levels

The National Sanitation Foundation is a Michigan-based product testing, inspecting, and certifying organization that, in addition to CBD, tests many products across other industries.

Though it is not yet explicitly clear exactly what testing data the MLB wants to see (other than the THC content limit), the NSF has ISO-accredited labs capable of providing the same caliber of testing (for microbes, heavy metals, residual solvents, etc.) that most third-party CBD labs do.

Aside from testing, another important, more subjective element that CBD companies will need to bring to a potential sponsorship deal with the MLB is a pre-existing emphasis on sports.

“It has to have a brand that represents sports,” said MLB Chief Revenue Officer Noah Garden when explaining the league’s intent for moving forward with CBD sponsorships. 

The MLB is part of the early wave of professional sport organizations warming up to CBD sponsorships, but they weren’t the first; the NBA has already done so, and the NHL is also preparing for CBD partnerships in the near future.

Especially considering the contentious history of THC and CBD products—many of which have already been openly embraced by pro athletes—in pro sports leagues, we are very pleased to see the MLB elevating the legitimacy of CBD products in a safe and sensible manner.

As always, we will continue to update you as more CBD developments surface.



via The CBD Insider https://thecbdinsider.com/news/mlb-greenlights-cbd-sponsorships/#utm_source=rss&utm_medium=rss&utm_campaign=mlb-greenlights-cbd-sponsorships


source https://renzverspaget.weebly.com/blog/mlb-greenlights-cbd-sponsorships

Tips for Vetting a Cannabis Trade Show: How to Measure Value and ROI

TESTSTSARDSAR

Tips for Vetting a Cannabis Trade Show: How to Measure Value and ROI by Gina Kranwinkel

The cannabis industry is growing and maturing. Along with it, trade shows are playing an evermore important role in educating about new products, services, and creative ways to expand businesses. Exhibitors are marketing a vast array of goods and services giving growers, processors, and retailers the convenience of one-stop shopping to keep their cannabis operations on the leading edge.

So, before you pay for your airline tickets and hotel rooms, how do you decide which trade shows are right for you? How do you know if they’re worth the time and money.

Vet the Members

Just as when you conduct background checks to vet your new employees and ensure their experience and reliability are what they say they are — the same should be done to verify the quality of exhibitors and speakers at the next cannabis event you choose to attend. 

One of the cornerstones of NACB is that our members are vetted — meaning, they have to pass a system of checks and balances to ensure they are ethical, legal, compliant, and much more. The events you attend should consider doing the same. Does the event take the time to verify and check into all who are exhibiting, speaking, and trying to solicit business from the industry? While this is a component we’d like to see, we know that this takes time and expense in implementing a vetting program. 

Until these vetting systems are in place with industry events, here are some of the steps you can take and questions to ask before buying your tickets:

What do your industry partners, colleagues, and friends say about this event? Did they believe they got their ROI?

Is the show sponsor a trade association you belong to or are at least familiar with? If so, you may be able to find some helpful reviews by people you trust and deepen the value of your association membership at the same time.

Does the organizer post a list of exhibitors on its website?

A little research should tell you if they’re offering goods and services of interest that are right for the industry.

Set up some meetings with attendees and vendors ahead of time to discuss business opportunities. Try to come home with some solid new ideas, if not deals.

There are no hard and fast rules, but another way to vet the quality of trade show exhibitors is to look at the cost of exhibitor space and quality of booth design. If it’s high-end compared to other shows, then you know exhibitors and attendees are expecting strong value from the chance to meet each other.  

Does the value justify the expense?

If you follow some of these trade show guidelines for vetting your participation, you will be on your way to measuring your ROI. Best of all, you’ll have solid opportunities and an education that will help carry your business further. 

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/tips-for-vetting-a-cannabis-trade-show-how-to-measure-value-and-roi/


source https://renzverspaget.weebly.com/blog/tips-for-vetting-a-cannabis-trade-show-how-to-measure-value-and-roi

Thursday, 23 June 2022

Something Edible with Laurie Wolf: Chicken Pot Pie Recipe

TESTSTSARDSAR

Something Edible with Laurie Wolf: Chicken Pot Pie Recipe by Patricia Miller

One of the ultimate comfort foods, this cannabis-infused pot pie will hit all the taste and feels buttons. If you don’t eat chicken you can substitute tofu, jackfruit, or even a vegetable like cauliflower or eggplant. Just cook the vegetables first, and change the broth to a vegetable stock. Remember that cannabis can take time to kick in, so don’t eat more, too much cannabis is an unpleasant experience. Just the right amount of cannabis? Delightful.

I infused this recipe with one of my favorite strains, Sirius Black. This beautiful, deep-purple, indica-dominant cannabis is a tiny bit tart and also has grape-like sweetness. I find that I am quite loquacious after imbibing in this strain. I like to freeze the butter in ice cube trays for later use.  

Laurie Wolf is the author of such cannabis cookbooks as Marijuana Edibles, HERB, The
Medical Marijuana Dispensary, and Cooking with Cannabis. Her recipes have been featured
in
High Times, Dope Magazine, Culture, and more. She is also the founder of Laurie +
MaryJane, an edible company offering everything from almond truffle bites to vegan chocolate
cookies. And remember, #Don’tFeartheEdible!

SERVES 4

What You’ll Need:

2 tablespoons butter

4 teaspoons canna-butter or canna-oil, at 5mgTHC per teaspoon

1 stalk celery, thinly sliced

1 carrot, peeled and sliced

1 teaspoon fresh thyme leaves, chopped

1/3 cup a.p. flour

2 cups chicken broth

1/3 cup half and half

1 cup frozen peas

3 cups cooked chicken, shredded or chopped

Salt and pepper

Flour (for rolling out the pastry)

1 box frozen puff pastry or two pie-crusts

1 large egg, beaten

Directions:

1. In a large sauté pan, over low heat, melt the butters. Sauté the celery, carrot and thyme for 10 minutes.

2. Add the flour to the mixture and cook for 2 minutes, stirring frequently. Add the broth, half and half, and mix well until the vegetables are coated and the mixture starts to thicken. Stir in the chicken. Season with salt and pepper to taste. Allow to cool slightly, about 20 minutes.

3. Heat oven to 340. 

4. On a floured surface, roll out the pastry and cut to fit the tops of 4 -8 ounce ramekins. 

5. Divide the chicken mixture among the 4 ramekins and top with the pastry. Brush the pastry with the beaten egg and make slits to allow the steam to escape while baking.

6. Bake for 25-30 minutes, until the crust is golden brown and the filling is bubbling.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/something-edible-with-laurie-wolf-chicken-pot-pie-recipe/


source https://renzverspaget.weebly.com/blog/something-edible-with-laurie-wolf-chicken-pot-pie-recipe

Wednesday, 22 June 2022

What Are the Top 10 Cannabis Economies in Europe?

TESTSTSARDSAR

What Are the Top 10 Cannabis Economies in Europe? by Marguerite Arnold

Things are starting to change in a hurry on the cannabis front across the EU. Here is a brief overview of the leading cannabis countries across the region as it experiences a European “summer of cannabis love.”

Things are definitely moving in Europe on the cannabis front this summer. Countries are beginning to see a post-Covid wave of enthusiasm if not continual reminders from the industry as it exists so far, to finally address lingering cannabis prohibition of both the medical and recreational kind.

Just as in the United States, where conservative states (like North Carolina) cannot deny at least medical efficacy anymore, there is a certain logic that is driving reform across Europe right now.

There has already been a raft of interesting announcements this spring – starting of course with Germany. But things are not just moving aus Deutschland.

Read on for a brief overview of the top ten cannabis countries in Europe

Germany

If there was a tipping point, it would be Germany’s to claim. The largest economy in Europe is going recreational – at least legislatively – this year. This is going to be a very interesting waterfall moment. Come 2024, at the latest, the cannabis map of Europe is going to look very different. Germany currently has three cultivators of EU GMP cannabis, scores of hemp farmers, multiple narcotics distributors, and a growing ecosystem of a country just pre-reform. Think a much higher regulated Colorado circa 2012 but with a very different sprache. It will also be in a position to rival London for fundraising – and not in Berlin but in Frankfurt. When Deutschland goes green, expect a tidal wave of reform to follow across Europe.

Holland

The land that created the eponymous symbol of reform – the coffee shop, is certainly in the heavy hitter column, no matter how many threats keep popping up to shut out tourists in Amsterdam. In the meantime, a national cultivation system that supplies such establishments outside of major cities is setting up to finally get going next year. And do not count out the country when it comes to medical cultivation – even if it is just for export.

Portugal

It looks like recreational reform is back on the national agenda after the Left Bloc raised the topic recently. The country whose world-famous laissez-faire approach to decriminalization (and copied by Oregon) is shaping up to be a major feeder market for the European medical biz. In the meantime, the calls for full reform, which were stymied last year with the fall of the old government, are clearly back on the table this summer.

Greece

Unlike their Dutch neighbours to the north, the Greeks are opening up the country to the cannabis industry because of foreign investment. It is also clear that medical tourism is going to be high on the agenda as things continue to cook. In the meantime, the country is beginning to export medical cannabis, but it is still not living up to its full potential. Give it a few summers, however, and the ability to travel, as a patient, to a warm, inviting climate where a new doctor will issue a prescription, will be understandably enticing – and to a global clientele.

Switzerland

The trial is on! Cities are continuing to announce their cannabis plans. Switzerland may be proceeding slowly and cautiously, with few participants, but right now they are the leader in rolling out a regulated industry of the recreational kind – and from scratch. Cultivation is also happening here, although it will not necessarily be the most economical export. Swiss farmers are competing against those in warmer climates – and with lower labour rates.

Italy

The country’s highest court may have blocked a referendum on reform this year, but medical cannabis cultivation is expanding, as is the hemp market. Beyond this, Italy is on the list of one of the top countries in the region to allow home grow by legislative muster. Despite being more conservative in many ways than Spain, the Italians are managing to beat them to the punch on the cannabis conversation. It may be happening in stranger ways, but right now, there is definitely a regulated industry that is popping and getting stronger.

Spain

Home of the cannabis club, Spain is teetering right now on the verge of medical reform at a federal level. It is an advancement, but there is so much more bubbling just beneath the surface. The clubs are not going to go away. The hemp industry is established. The country has pharmaceutical-grade cannabis being shipped to other European countries. It is certainly ahead of other countries, but there is a great deal of resistance to full and final reform. Don’t expect Spain to be a market leader, but rather a follower.

UK

If certain members of Parliament get their way, the UK’s CBD biz could go into overtime. The reason? The proposed elimination of Novel Food applications. In the meantime, there are close to 6,000 products on, or close to, the market. Medical cannabis cultivation and extraction projects are also underway, especially on the islands surrounding the mainland. Beyond this, the mayor of London, the country’s largest city, is loudly and internationally suggesting that, at minimum, cannabis be decriminalized in certain boroughs of London and that the police might stop racially profiling minor drug offenders. The British investment market, however, is one of the hottest in the world right now. If you are looking for financing anywhere in Europe, you cannot ignore London right now.

Luxembourg

The country’s government has been dangling recreational cannabis reform like a carrot for the last four years. With time running out on fulfilling their pledge, the country is apparently moving forward with a surprisingly conservative home grow proposal at a federal level. When Germany passes reform legislation, expect Luxembourg to be close behind. This was the pattern on the medical front too. It is a rich, but small country. Major policy changes like this are best done by larger countries in the bloc.

The Czech Republic

The CR has taken forward steps on this entire conversation consistently over the last five to seven years. Right now, medical reform is in full swing. Even more interestingly, much like Thailand, the country is more concerned with treating patients than enforcing EU GMP standards. This means that when Germany goes recreational, expect the Czechs to follow shortly thereafter.

This article first appeared on Internationalcbc.com and is syndicated here with special permission.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/what-are-the-top-10-cannabis-economies-in-europe%ef%bf%bc/


source https://renzverspaget.weebly.com/blog/what-are-the-top-10-cannabis-economies-in-europe

New Research Into Terpenes Could Change Medicine Forever

TESTSTSARDSAR

New Research Into Terpenes Could Change Medicine Forever by Patricia Miller

You’ll often hear people say cannabis science is in its infancy. While it’s true there is much more to learn about the plant, some regions of the world have been studying cannabis intensely for decades.

The field of cannabis science was pioneered by Raphael Mechoulam in the 1960s. His research, based in Israel, laid the foundation for our modern understanding of the herb.

Nearly 60 years later, Israel remains a leading force in the study of cannabis. 

Nadav Eyal, CEO and co-founder of Eybna Technologies, is building on this body of research and pioneering his own studies on terpenes, cannabinoids, and their interactions with the endocannabinoid system.

In 2020, Eybna discovered a cannabinoid formulation that effectively blocked the novel coronavirus from penetrating living cells. The combination, known as the NT-VRL formulation, is now undergoing clinical study as a potential treatment for the disease. 

While NT-VRL is a remarkable discovery, it may ultimately pale in comparison to Eybna’s more recent revelation around receptor-specific cannabinoid formulations.

In this interview, Eyal discusses what inspired him to study cannabis and how his latest research will change the industry forever. This conversation has been edited for length and clarity. Hear the whole interview at https://ift.tt/zGaqN6h.

Cannabis & Tech Today: What drew you to study cannabis?

Nadav Eyal: My journey through the cannabis industry started back in 2008. I was very involved in my mother’s treatment for cancer. That’s when I was exposed to the term medical cannabis, but at the same time in Israel, it was very early days for the medical program.

Unfortunately, my mother didn’t use cannabis and she passed away. The same year, I joined military intelligence in the army. So this was a turning point in my life that drew me into the cannabis industry. In military intelligence, I was doing mostly data science, big data, and understanding how data can help us to make better decisions.

Ultimately, I found we could use data science methods to change the language from conversations about strains, such as OG Kush and Super Lemon Haze, to conversations about molecules such as limonene, and CBN, and THCV, which allows us to apply real science to the cannabis industry.

It also allows us to avoid the inconsistency of cannabis products in order to let people that have real medical conditions enjoy the benefits of the plant.

C&T Today: Last year, you found a combination of cannabinoids with the potential to treat or even prevent coronavirus infections in human lung cells. When did you realize you had made a significant discovery?

NE: In this research, one of the things that I remember is the phone call I got from the lead manager asking, “What the hell did you give us here?” Because what happened is that in the research, she found that the NT-VRL formulation was blocking the penetration of the coronavirus to the cells.

This opened our eyes to terpenes being a very useful immunity product. So we decided to do another test versus a cytokine storm. 

We found that the same NT-VRL formulation worked better than dexamethasone, which is a steroid used in hospitals to treat conditions of inflammation.

So these two [findings] together were strong enough for us to take it a few steps forward and prepare a clinical study in Israel.

It is going to take the formulation we developed and test it versus coronavirus in human trials. This is ongoing right now, and we’ll be happy to share more results moving forward.

C&T Today: You recently developed a line of phytochemical formulations targeted to specific wellness goals. How are these formulations unique in the industry?

NE: Since the beginning of the company we have been envisioning this line that we launched in the last two months.

It’s basically a new category of product called receptor-specific formulations. So what does it mean? If we try to break down how the different compounds in the plant are activating the human body, the smallest resolution we can measure is the interaction between one compound and one receptor.

So for example, we are familiar with the endocannabinoid system and the CB1 and CB2 receptors. The endocannabinoid system itself has six small receptors.

And the same as the endocannabinoid system, we have other systems in the body such as the dopamine system, the serotonin system, and the GABA system.

All of them are being activated by the phytochemicals found in the cannabis plant. So in the last six years of research, we were mapping the interactions of thousands of compounds in the cannabis plant with different receptors in the human body. 

We were able to measure which one of them is activating which type of receptors in our body.

Today, we are selling formulations that are composed only of the ingredients that are effective to produce a certain effect, such as pain relief or sleep.

What people are still underestimating is the fact that when you have a thousand compounds, which is whole-plant medicine, there are some compounds that are contradictory to each other.

So if you want a sleep medication, you do not necessarily want the compounds that are good for daytime effects and vice versa.

So the receptor-specific line is the first step to be able to introduce globally a line of natural formulations that are targeting indications that are important for human wellness.

And everything we are now doing is to take the conversation from getting high to a conversation about wellness.

Because there are people in the recreational markets that are looking to just get high, but there are a lot of people worldwide, especially the elderly population, that can benefit from the cannabis plant much more than from the pharmaceutical drugs they are using today. 

But until we introduce products that are actually effective, people will never switch.

So we are already partnering with some of the largest brands in the cannabis industry and the CBD industry to launch different effect-specific products that are all using our receptor-specific formulations.

I believe 2022 is going to be a year of change and innovation in the industry.

C&T Today: Thanks to Israel’s approach to medical cannabis, you’re able to conduct really thorough research. You’re doing trials with living organisms, conducting cellular research, and creating computer-aided investigations. This is a lot of data that’s adding to the understanding of cannabis on a global level. What have you found most surprising during your experiments?

NE: First of all, I’m surprised that not a lot has been done on cannabis. There are so many new things we were able to discover in the last three years of research. Every day, we are learning that there are unknown capabilities for this plant. 

In collecting a lot of data from a lot of different sources, we can actually solve the hard questions. So, sometimes in life you need different angles and different points of view to understand the full picture.

By doing research, from computational biology to In Vitro, and connecting it with the data from patients and ethnobotanical data, and bringing everything to the table for the R&D team of Eybna, we were able to come up with insights that are very innovative and hopefully will be very valuable to the whole industry. 

The last part is the fact that the cannabis industry is still building itself and everything is possible. There is a very much an increased demand for innovative products coming from California and the rest of the U.S.

The ability to see how research is being used, then coming back into products, and turning it into the ability to improve the quality of life of people worldwide — it’s just a cycle that is exciting. 

What we are going to see is that the cannabis industry as a whole is going to change — not just the tobacco and alcohol industry — but is going to completely change also the pharmaceutical industry and allow people to enjoy what we recognize today as preventative medicine.

This will allow this field of preventative medicine to become scientifically supported and eventually to dramatically improve quality of life on a global scale.

That’s exactly where Eybna is looking in the next five years. 

Cannabis is still in its beginning. There is so much this plant is going to bring to the world.

This article was first published in the winter 2021 issue of Cannabis & Tech Today. Read the full issue here for free.

A link to your site, with your site's name and description as anchor text.



Via https://cannatechtoday.com/new-research-into-terpenes-could-change-medicine-forever/


source https://renzverspaget.weebly.com/blog/new-research-into-terpenes-could-change-medicine-forever

CBDistillery To Launch THCV Study

Moving onto the next “pathfinder mission,” as CBDistillery is calling their intensive research campaign spanning various hemp products an...